Study Objectives: Thirty to sixty percent of cancer patients have insomnia symptoms, a condition which may lead to numerous negative consequences and for which an efficacious management is required. This randomized controlled trial aimed to assess the efficacy of a 6-week home-based aerobic exercise program (EX) compared to that of a 6-week self-administered cognitive-behavioral therapy for insomnia (CBT-I) to improve sleep in cancer patients.
Introduction
Insomnia is among the most prevalent symptoms associated with cancer with 30% to 60% of patients reporting this condition, and approximately 20% of them meeting the diagnostic criteria of an insomnia syndrome. This prevalence of insomnia syndrome is at least twice as high as in the general population [1, 2] . Sleep difficulties may occur before and during cancer treatment, and may persist long after their cessation [2] [3] [4] [5] . Cancer treatments and their side effects are factors significantly contributing to the development and persistence of insomnia [6] . The consequences of insomnia are numerous and can negatively affect both psychological and physical functioning [7] [8] [9] [10] . Patients with insomnia commonly report symptoms of fatigue, psychological distress, impaired daytime functioning, and disrupted cognitive functioning [11] [12] [13] . Yet, the economic burden of insomnia has been found to be very high in the general population and much more costly than the insomnia treatment itself [14] . In order to reduce the individual and societal burden associated with this condition, it is essential to provide effective treatments to cancer patients with sleep difficulties.
Cognitive-behavioral therapy for insomnia (CBT-I), a multifaceted treatment that generally includes stimulus control strategies, sleep restriction, cognitive restructuring, and sleep hygiene education, is the treatment of choice for chronic insomnia and has been recommended as the first-line intervention for cancerrelated insomnia [15, 16] . Indeed, an increasing body of research supports the efficacy of CBT-I specifically in cancer patients [17] [18] [19] [20] [21] [22] [23] . Results of previous trials have revealed significant improvements of subjective measures of sleep, a decreased hypnotic medication consumption, a reduction of anxiety, depression, and fatigue symptoms and an increased global quality of life. A recent review and meta-analysis of the available literature revealed between-groups differences, when compared to control conditions, that corresponded to medium to large effect sizes and improvements that were durable up to 6 months after the intervention [24] .
However, CBT-I is not widely accessible mainly due to the lack of trained professionals in cancer settings to administer this therapy. Other barriers include the costs of sessions and the constraints related to insurance reimbursement [25] . A possible solution is to provide a self-administered version of this therapy. A meta-analysis of studies conducted in the general population showed that self-administered CBT-I efficaciously improves subjective sleep, with group-by-time interaction effects of a low to medium size relative to controls [26, 27] . In the context of cancer, Savard and colleagues (2014) compared a standard CBT-I administered by a professional with a video-based CBT-I. Both intervention groups showed significantly greater improvements of subjective sleep measures as compared to a no-treatment control group at posttreatment. In addition, a small randomized controlled trial (RCT) found that a web-based CBT-I was superior to a waiting-list control condition to decrease sleep disturbances (assessed subjectively with the Pittsburgh Sleep Quality Index; PSQI) at posttreatment, changes that were clinically significant [28] .
Another even more accessible alternative could be exercise (EX). Recognizing its various benefits, the Canadian Cancer Society and the National Cancer Institute in the United States recommend that cancer patients remain as active as possible throughout treatment and survivorship phases [29, 30] . Surveys and crosssectional studies have shown associations between higher levels of physical activity and better sleep in cancer patients [31] [32] [33] .
Also, a number of quasi-experimental and small RCTs have evaluated the effect of EX interventions on sleep in this population [34] [35] [36] [37] [38] . Two reviews summarizing this literature have been published [39, 40] . However, no firm conclusions could be drawn from these reviews as included studies generally assessed sleep with poor measures (e.g. one-item scale) or had several significant methodological limitations. More recently, we published a systematic review and meta-analysis of the literature assessing the effect of EX interventions on sleep in cancer patients. Twenty-one studies were included in the review, of which 17 were RCTs. The meta-analysis conducted on RCTs revealed no significant effect on the subjective and objective sleep measures analyzed [41] . This lack of significant effect could be due, at least in part, to a floor effect given that participants of reviewed studies were not selected on the basis of significant sleep impairments at baseline. Retrieved studies were also characterized by many methodological limitations (e.g. lack of statistical power, no intention-to-treat analyses, attrition bias, lack of control for potential confounders such as usage of sleep medication). Hence, it remains to be established whether EX interventions produce a significant and durable effect on sleep in cancer patients. In particular, comparative studies with treatments whose efficacy is well established for treating cancer-related insomnia, such as CBT-I, are greatly needed.
The main goal of this study conducted in cancer patients was to evaluate whether a home-based EX program leads to a reduction of insomnia severity (measured with the Insomnia Severity Index; ISI) that is significantly non-inferior to that of a more standard self-administered CBT-I (non-inferiority hypothesis) at posttreatment and at 3-and 6-month follow-ups. It was postulated that the EX intervention would be statistically noninferior to CBT-I in producing a reduction of ISI scores (primary outcome) at posttreatment but would be inferior at follow-ups. Secondary goals of this study were to compare the effects of both interventions on various sleep parameters (subjective and objective) at posttreatment and at 3-and 6-month follow-ups (superiority analyses). It was hypothesized that both interventions would lead to significant improvements of various secondary sleep outcomes (PSQI, sleep diary, and actigraphy) at posttreatment but that CBT-I would be associated with better sustainment of treatment effects over time. This last hypothesis was posed because CBT-I targets factors associated with the maintenance of insomnia over time (maladaptive sleep behaviors and dysfunctional beliefs about sleep) [42, 43] and because continuing to be physically active in the absence of support is a challenge for many people [44] .
Method

Participants
Eligibility criteria
Inclusion criteria were: (1) aged between 18 and 80 years old; (2) have received a non-metastatic cancer diagnosis for which the adjuvant treatment (except hormone therapy) ended within the past 6 months (given the expected and demonstrated benefits of physical activity during the rehabilitation period) [45] ; (3) have insomnia symptoms, as indicated by a score of 8 or greater on the ISI [46] ; (4) not currently regularly exercising, that is, less than 90 minutes of moderate to vigorous intensity aerobic EX OR less than 150 minutes of low-intensity EX per week depending on the EX intensity reported by participants; (5) be able to read and understand French; and (6) have a physician's written permission to engage in an aerobic EX program. Exclusion criteria were: (1) having a sleep disorder other than insomnia (e.g. obstructive sleep apnea); (2) having a severe medical condition that could interfere with exercising (e.g. pulmonary disease, coronary artery disease) or a contraindication to engage in an EX program (e.g. musculoskeletal disease); and (3) having a severe psychiatric disorder (e.g. schizophrenia, bipolar disorder) or severe cognitive impairments (e.g. Alzheimer's disease) as reported by the patient. Patients were allowed to do moderate to vigorous EX up to 90 minutes at study entry because it is the maximum duration from which an increase of 60 minutes per week would not exceed 150 minutes.
Recruitment
Participants were recruited between June 2012 and August 2014. Forty-one participants, male and female, were recruited at the hospital L'Hôtel-Dieu de Québec (CHU de Québec-Université Laval). Participants were mainly approached by a research assistant at the radio-oncology department, who briefly introduced the study and collected contact information of those interested in the project. Other participants were recruited through a letter that was handed by the radio-oncology team to patients who were about to end their radiation therapy. Then, a phone screening was conducted to assess the eligibility criteria and explain the project in detail. The PRIME-MD questionnaire was administered over the phone to assess the presence of a severe psychological disorder (exclusion criterion). At this time, participants were also informed that they needed to ask their physicians to deliver a medical clearance in order for them to perform an aerobic EX program of a moderate intensity. Eligible and interested patients then received by mail the written consent form which they were invited to sign, along with the first battery of questionnaires. Figure 1 shows the participants' flowchart and detailed reasons for exclusions. The overall participation rate was 63% (41/65 of eligible patients). The main reason for exclusion was practicing more than 90 minutes of moderate to vigorous intensity aerobic EX per week at baseline (n = 31, representing 25.4% of all exclusions). Six participants (30%) assigned to the EX group and two (10%) assigned to the CBT-I group dropped out during the course of the study, for a total dropout rate of 20%. This study was approved by the research ethics committee of CHU de Québec-Université Laval.
Study design
This pilot RCT included two experimental conditions (ratio 1:1): self-administered CBT-I (n = 21) and home-based EX intervention (n = 20). Participants were assessed at pretreatment and posttreatment (about 6 weeks after baseline), as well as at 3-and 6-month follow-ups. A non-inferiority study design was used. This type of design is indicated when the main study goal is to compare the efficacy of a new treatment (EX) to that of a standard one (TCC-I) in order to determine if the new treatment has a comparable efficacy [47, 48] . In a non-inferiority trial, contrary to usual testing, the null hypothesis postulates that the experimental treatment is inferior to the standard one if its effect is below a pre-established limit difference (also called clinical margin). For the purpose of this study, a clinical margin of four points on the ISI was used, which corresponds to half of the score that is considered to be a clinically significant change [49] . This appears to be a conservative clinical margin given the general recommendation to use the smallest change value that may be clinically significant [48] . A standard (superiority) design was used for the secondary goals.
Randomization and allocation concealment
The randomization sequence was prepared by a biostatistician using a random permuted-block (size = 6) procedure with SAS 9.3 (SAS Institute, 2011). Investigators and research assistants were blind to the allocation sequence that was concealed in opaque and sealed envelopes until participants completed all baseline measurements. The graduate student in charge of the project (J.M.) or a research assistant opened the envelope in the presence of the participant when his/her eligibility was confirmed (following the physical assessment).
Sample size justification and power analyses A priori power analyses were conducted to determine the sample size needed to test the study hypotheses. More specifically, a sensitivity analysis was performed based on the recommendations of Hwang and Morikawa [50] . With a standard 80% power and an alpha level of 5% unilateral (given the unilateral direction of the non-inferiority hypothesis), the analysis showed that a sample of 20 participants per group (total N = 40) would have a sufficient power to test the non-inferiority hypothesis with a clinical margin of 3.5 units on the ISI. A power (sensitivity) analysis was also performed for superiority hypotheses, for an experimental design of 2 groups × 4 times with a total sample of 40 participants expected. The results showed that a total sample size of 40 would detect a minimal effect size of d = 0.29 for the group × time interaction at a standard power of 80%, which corresponds to a small effect [51] .
Procedure
Pretreatment assessment
Eligible participants were sent by courier a battery of selfreport scales to complete at home, containing a 2-week daily sleep diary and an actigraphic recorder to be worn during seven consecutive 24-hour periods. After the completion of measures, participants had their physical fitness evaluated by a professional kinesiologist at the University Laval Kinesiology Clinic. None of the patients were excluded at that point. The graduate student in charge of the project (J.M.) then met the participant at the clinic to proceed with the randomization. When the participant was assigned to CBT-I, the treatment material and relevant explanations were provided and, when the participant was allocated to the home-based EX program, he/she again met the kinesiologist to develop a personalized 6-week EX program.
Intervention phase
The intervention phase lasted 6 weeks. During that phase, all participants completed a daily sleep diary and a daily EX diary. Moreover, a weekly phone call from a member of our research team took place to know how participants were doing with the intervention they were assigned to, to answer their questions, if needed, and to enhance treatment adherence (e.g., by reinforcing the importance of pursuing treatment even in the absence of perceived improvements). Participants were also asked to complete the Treatment Perception Questionnaire after the first and fifth intervention week.
CBT-I intervention
The self-administered treatment package is composed of a 60-minute video (DVD format) and six booklets. Each week, participants had to watch a video segment (5-20 minutes each) and read a booklet. CBT-I includes behavioral (i.e. stimulus control therapy, sleep restriction), cognitive (i.e. cognitive restructuring), and educational (i.e. sleep hygiene) strategies. More details about this video-based intervention, slightly adapted from the standard CBT-I protocol [42] , can be found elsewhere [52] . Patients were phoned on a weekly basis to answer their questions and to reinforce treatment adherence.
EX intervention
The EX program was based on the recommendations of the American College of Sport Medicine (ACSM) [53] . The general goal was to do 3 to 5 20-30 minutes sessions per week of aerobic EX with a gradual increase over time until 150 minutes of EX per week was attained. However, the programs were individualized based on the participant's initial physical condition. For instance, for participants who were fairly active at baseline (i.e. near the maximal cutoff allowed for inclusion in study), the final objective was to increase their practice by 60 minutes by the end of the sixth week. Patients who were doing up to 150 minutes of low-intensity EX at study entry were instead instructed to increase the EX intensity. EXs had to be of at least a moderate intensity, thus corresponding to a perceived exertion rate between 3 and 5 on the modified Borg scale [54] . Participants were free to choose the type of aerobic EX they wanted in order to maximize their motivation to engage in and adhere to their EX program, including brisk walking, jogging, swimming or a combination of different aerobic EXs. Again, patients were called every week to answer their questions and to reinforce treatment adherence. Additionally, a follow-up phone call with the kinesiologist was also conducted around the third intervention week to pinpoint difficulties encountered and to make changes to the EX prescription if necessary. The only material these patients received was a one-page document providing some general explanations and outlining the individualized EX program.
Posttreatment and follow-up assessments
At posttreatment, as well as at 3-and 6-month follow-ups, participants completed the same battery of self-report scales at home (including both sleep and EX diaries for 14 days) and were asked to wear the actigraphic recorder at each time assessment for seven continuous 24-hour periods. Participants received $20 (Canadian) for each time point completed.
Measures
Unless otherwise specified, French (Canadian) versions of measures used have been empirically validated or developed by the authors of the original version.
Sleep and EX measures
Insomnia Severity Index [42] . The ISI includes seven items which evaluate, for the previous 2 weeks, the perceived severity of difficulties falling asleep, difficulties maintaining sleep and early morning awakenings, as well as the degree of dissatisfaction with current sleep, the degree to which sleep difficulties interfere with daytime functioning, the degree to which the deterioration of functioning related to the sleep problem is noticeable by others, and the level of distress or worry caused by the sleep difficulties (rated on a scale from 0 ["not at all"] to 4 ["very much"]). The ISI has been empirically validated among cancer patients and a score of 8 or greater is used to detect clinically significant insomnia symptoms (95% sensitivity), while a score of 15 or greater suggests the presence of an insomnia syndrome [46] . Pittsburgh Sleep Quality Index [55] . This questionnaire was developed to assess the subjective sleep quality of the previous month on seven components: sleep latency, sleep duration, daytime dysfunction, sleep disorders, use of sleep medication, habitual sleep efficiency and subjective sleep quality. The questionnaire consists of 19 items using a Likert scale ranging from 0 ("no difficulty") to 3 ("severe difficulties"). The total score ranges from 0 to 21 with a higher score indicating a poorer sleep. A total score >5 suggests the presence of significant sleep difficulties with a sensitivity of 89.6% and a specificity of 86.5% for distinguishing between good and poor sleepers (kappa = .75, p < .001). The internal consistency (α = .83) and the test-retest reliability (on average 29 days later, r = .83) of the scale were supported in the general population. Support for the validity and good psychometric properties in cancer patients is also available [56] .
Sleep diary. The following variables were derived from the sleep diary: sleep onset latency (SOL; time from lights out to sleep onset), number of nocturnal awakenings, wake after sleep onset (WASO; time spent awake after initial sleep onset), total wake time (TWT; sum of all awakenings, from lights out until the last awakening), total sleep time (TST; sum of all sleep periods from initial sleep onset until last awakening), sleep efficiency (SE; TST divided by total time in bed [TIB]), and hypnotic usage.
Actigraphy. The Actiwatch-2 (Philips, Respironics, Andover, MA) is a small, waterproof, non-intrusive actigraphy device that is worn on the wrist. Following usual recommendations, patients were instructed to wear the actigraphic recorder on their nondominant hand for seven consecutive 24-hour periods at each time assessment [57] . By calculating orientation and movement, the Actiwatch estimates sleep-wake activity and provides an objective measure of the same sleep parameters as the sleep diary. In the current study, actigraphic data were also used to objectively measure the participants' physical activity level at four time points. The validity of actigraphy has been demonstrated, both for the evaluation of sleep in insomnia patients [58] , as well as the level of physical activity [59] . EX diary. An EX diary was developed specifically for the needs of the current study. Participants of the two groups completed this measure daily during the 6-week intervention phase, as well as for 2 consecutive weeks at posttreatment, 3-and 6-month follow-ups. Specifically, they were asked to document, for each day, the type of EX they performed, its duration and intensity (perceived effort according to the modified Borg scale). This allowed us to calculate the frequency and the total duration of EX performed per week, and also to assess patients' adherence to the EX program.
Godin Leisure-Time Exercise (GLTEQ) [60] . The GLTEQ is a 4-item questionnaire that evaluates the habitual physical activity performed, during free time in a typical weekly period, of high, moderate and low intensity, separately. A correlation of r = .35 was obtained between the reported frequency of high-intensity EX on this questionnaire and the VO2 max. The 2-week test-retest reliability of this instrument is high (r = .74 to .80). The GLTEQ is commonly used in oncology settings [61] . This questionnaire was used on the four main time points of the study.
Other measures included Treatment Perception Questionnaire [52] . This questionnaire, developed by our research team, assesses participants' satisfaction with the content of the booklets and the video containing CBT-I (13 items), the contact person (eight items), and global satisfaction with the intervention (e.g. interest towards the proposed 
Number of nights (weekly strategies, global sleep improvement; seven items). A similar questionnaire was developed for the EX intervention and documented participants' global satisfaction with the program (nine items) and the kinesiologist (seven items). The TPQ was administered at posttreatment only.
Treatment Credibility and Expectancies for Improvement Scale. The questionnaire was adapted by our team from the questionnaire developed by Borkovec and Nau [62] . It includes five questions rated on a Likert scale ranging from 0 ("not at all") to 3 ("very much") and evaluates participants' therapeutic expectancies and the credibility they give to the treatment proposed. Before they were randomized, all patients completed two versions of the questionnaire, one for each treatment. The version corresponding to their group allocation was completed again after the fifth intervention week. One item was added at pretreatment to ask patients if they had a preference between the two interventions on a scale from −3 ("strong preference for EX"), 0 ("no preference") to 3 ("strong preference for CBT-I").
Demographic and medical data. Demographic data collected on this questionnaire include age, marital status, level of education, socioeconomic status, tobacco, alcohol, and caffeine consumption, time since cancer diagnosis, cancer type and treatments received, presence of comorbid psychological or medical conditions, and medication use. The participants' medical records were consulted to corroborate cancer-related data and document the cancer stage.
Statistical analyses
Data were entered by J.M. and verified independently by another research assistant. Examination of missing data, outliers and distributions was performed using standard procedures. No missing data was imputed. Analyses were performed using an intent-to-treat approach. All analyses were conducted using the SAS 9.4 software (SAS Institute, Cary, NC) and the alpha level was set at 5%, two-tailed (except for the non-inferiority analysis, where the alpha level was set at 5% one-tailed). In order to assess changes on study variables within and between conditions, 2 groups (CBT-I vs. EX) × 4 times (pretreatment and posttreatment, 3-and 6-month follow-ups) analysis of variance (ANOVA) mixed model analyses were completed [63] . Given the exploratory nature of these analyses and the sample size, no statistical correction for multiple comparisons was done in order to maximize the statistical power of inferential tests. Simple effects were conducted to test temporal changes between time points. Based on the suggestions of Frigon and Laurencelle [64] , it was planned to statistically control only variables showing a moderate association r ≥ .30 [51] with at least two of the main dependent variables (ISI, PSQI or SE%). Demographics, cancer characteristics and treatments, medication use, psychological difficulties (past and current) and health-related data were investigated as potential covariates. Since no one was found to meet the above-described criterion, no covariate was included in the analyses. Three categories of EX intensity were calculated using actigraphy data: low intensity (0 to 1534 counts per minute), moderate (1534 to 3959 counts per minute) and vigorous (≥3960 counts per minute) [65] . Finally, effect sizes (Cohen's d) for time effects were calculated as the raw difference between assessment points (e.g. pretreatment vs. posttreatment) divided by the RMSE of the mixed models for all study outcomes.
Results
Participants' characteristics
All participants were French-Canadian and Caucasian. The participants' demographic and medical characteristics are presented in Table 1 . The mean age of the sample was 57.1 years old, and it was mainly composed of women with breast cancer (n = 22; 54%). A majority of participants were married or in a common-law relationship (n = 27; 66%) and had a university degree (n = 24; 59%). All participants received radiation therapy, and a large proportion of them underwent a surgery beforehand (n = 32; 78%). More than a third of the participants also received chemotherapy (n = 15; 37%). Finally, 46% of the sample were hypnotic users at baseline, with an average frequency of use of 2.5 (3.1) nights per week. No significant between-group differences were found on any demographic and medical variable at baseline.
Non-inferiority analyses
The CBT-I group showed a reduction of −4.56 points on the ISI from pretreatment to posttreatment (from 14. with a confidence interval of −0.94 to 7.67). At the 6-month follow-up, the CBT-I group showed a reduction of −3.04 points on the ISI relative to pretreatment (14.8 to 11.77; d = −0.52) as compared to a decrease of −6.63 for the EX group (from 16.0 to 9.37, d = −1.14; between-group difference of 3.59 with a confidence interval of −0.24 to 7.42). Since both confidence intervals fall within the clinical margin of four points, it is possible to conclude that EX was non-inferior to CBT-I in reducing ISI scores at follow-up. Figure 2 show mean scores obtained on subjective sleep parameters at each time point, in both groups. No significant group × time interaction was found on any variable, except on PSQI scores. However, simple effects revealed no significant between-group difference on this outcome at any time assessment. The interaction was marginally significant on ISI scores (p = .06) but, again, simple effects on between-group differences were all nonsignificant. Significant main time effects were obtained for all variables (all ps < .05) and simple time effects were significant in both groups on all variables, with the exception of SOL and TIB for EX and early morning awakenings and TIB for CBT-I. Pretreatment versus posttreatment effect sizes of a moderate magnitude were observed (ds > 0.70) for SOL, . Finally, the main group effects were not significant for any outcome and the only simple between-groups significant difference was at posttreatment on the total TIB which was shorter in the CBT-I group (p = .03). Interestingly, SOL decreased under the 30-minute clinical threshold at posttreatment in both groups, an improvement that was sustained at both follow-ups. In addition, SE increased by more than 8% in both groups at posttreatment, although it was still falling under the 85% threshold. SE continued to improve at follow-up reaching 84% and 85% for CBT-I and EX groups, respectively, at the 6-month evaluation. On the other hand, mean ISI and PSQI scores remained above the clinical cutoff at each time point, in both groups. Regarding the weekly mean days of consumption of prescribed hypnotic and anxiolytic medications during the course of study, no significant group × time interaction was found, nor time or group effects (all ps > .05). However, CBT-I patients more importantly reduced their utilization of these medications from pretreatment to posttreatment as indicated by a superior effect size in CBT-I (d = −0.35 for CBT-I vs. d = 0.03 for EX).
Treatment effects on sleep parameters at posttreatment and follow-ups (superiority analyses)
A different pattern of results was obtained on objective sleep variables as assessed with actigraphy (Table 3) . Specifically, none of the group × time interactions, main time effect, and main group effect was significant. The only significant time effects from pretreatment to posttreatment were obtained in the CBT-I group only on early morning awakenings (reduction of approximately 5 minutes; p = .01) and WASO (reduction of approximately 7 minutes; p < .01). It is noteworthy, that SE was below the clinical threshold of 85% in participants of both groups, at each time point. Effect sizes of pretreatment versus posttreatment differences were all of a small magnitude (all ds ≤ 0.40), with the largest effect size obtained on TIB in the CBT-I group.
Complementary analyses
Integrity of the interventions
To assess the integrity of the CBT-I intervention and the possible contamination of the EX group, two behavioral indices were calculated based on sleep diary data: the regularity of the sleep schedule 1 and the number of naps per day. This provided measures of adherence to two stimulus control instructions, that is to keep a sleep/wake schedule as regular as possible and to reduce the number of naps. No group × time interaction was found on any of these indices (Table 4) . Moreover, no significant time effect was found between pretreatment and posttreatment in CBT-I participants, nor in EX patients, on the regularity of the sleep schedule, while a significant reduction of napping was observed in both intervention groups (significant time effects, ps < .05).
To evaluate the integrity of the EX intervention in increasing physical activity and the possible contamination of the CBT-I group, two indices derived from the EX daily diary (the only measure completed during the 6-week intervention) were used: (1) the proportion of participants reaching the recommendation of 150 minutes of moderate-vigorous aerobic EX per week at the end of the program (week 5 or 6); and (2) the proportion of participants who increased their practice by 60 minutes or greater of moderate-vigorous physical activity between intervention week 1 and week 5 or 6. The mean weekly EX duration attained during the 6-week intervention phase, by each intensity category, is presented in Table 5 . Although there was no significant time effect and no significant group × time interaction (all ps > .05), there was a general increase of self-reported time spent in moderate exercising until week 3 or 4, followed by a decrease in both groups. Chi-square tests were conducted to assess between-group differences on the attainment of both EX recommendations at the end of the program. Results indicated that 60.0% of EX participants reached the recommendation of ≥150 minutes of moderate-vigorous aerobic EX, as compared to 42.9% of CBT-I participants, a difference that was not significant, χ 2 = 1.2, p = .27. In addition, 55.0% of EX participants increased their EX practice by ≥60 minutes of moderate-vigorous intensity, as compared to 38.1% of CBT-I participants, again a difference that was not significant, χ 2 = 1.18, p = .28.
Moderating role of treatment preferences at baseline
At pretreatment, 60% (n = 21) of participants indicated that they had a preference (between "moderate" and "high") for the EX intervention, whereas six participants (17%) only had a preference (between "low" and "high") for CBT-I (Table 6 ) and eight participants (23%) had no preference. More patients assigned to the CBT-I group than to the EX condition (12 participants vs. 9) initially indicated they would have preferred an EX program. To evaluate the possible contribution (moderator effect) of being assigned to the condition for which the participant expressed having at least a low, moderate or high preference (i.e. being matched), a mixed model matched × condition × time ANOVA was performed on the main sleep outcomes (ISI, PSQI, and ES) at pretreatment and posttreatment. Participants with no preference were considered matched by default. No significant two-way moderator interaction (matched × time for each condition) was found in any group (ps > .05; see Table 7 and Figure 3 ) on the ISI, the PSQI and SE. However, a significant pretreatment versus posttreatment time effect in the direction of an improvement was found in the CBT-I "mismatched" subgroup on the three sleep variables while an improvement was found only on PSQI for the CBT-I "matched" subgroup. A different profile of results was observed in EX patients in which no significant pretreatment versus posttreatment time effect on any outcome was found in the mismatched subgroup. The EX matched subgroup showed a significant improvement on ISI scores and SE values.
Given that 51% of the sample reported having a preference for the EX intervention, we further looked at the contribution of being matched to the preferred treatment on the attainment of the two EX recommendations described above. No significant moderating role in the attainment of these recommendations was obtained (data not shown; all ps > .05). For example, in the CBT-I group, 42.8% (3/7) of matched participants reached the recommendation of 150 minutes of moderate-vigorous aerobic EX per week at the end of the program compared to 50.0% (6/12) of mismatched patients (patients who initially preferred 1 The regularity of the sleep schedule was estimated as the SD of bedtime/arising time for the 14 diary days, with the expectation that the variability of the sleep schedule would be more importantly reduced in CBT-I at posttreatment than in the EX group. EX), χ 2 = 0.09, p = .76. Similarly, in the EX group, 61.5% (8/13) of matched participants reached this recommendation as compared to 66.7% (2/3) of mismatched (patients who initially preferred CBT-I) participants, χ 2 = 0.03, p = .87.
Evolution of treatment expectancies for improvement
A significant group × time interaction was found on treatment expectancies scores: F (1, 31) = 12.25, p = .001, thus indicating that scores obtained on this questionnaire had a different evolution across groups. While CBT-I participants reported an increase in treatment credibility and expectancies scores from baseline (9.9) to the fifth week of intervention (11.3), EX participants obtained decreased scores (from 12.0 to 9.6).
Discussion
The main goal of this non-inferiority RCT, conducted in patients with mixed cancer sites, was to compare the efficacy of a homebased EX intervention to a self-administered CBT-I, considered as the standard treatment, for reducing insomnia severity at posttreatment and at 3-and 6-month follow-ups. Other study goals were to compare, using superiority analyses, the effects of these two non-pharmacological home-based interventions on sleep measured subjectively and objectively at posttreatment and at 3-and 6-month follow-ups. Results only partially support the initial study hypotheses. More specifically, results of the non-inferiority analysis showed that EX was significantly inferior to CBT-I in reducing insomnia symptoms at posttreatment as measured with the ISI. Although the between-group difference in the reduction of mean ISI scores at posttreatment was rather small (−0.65), the confidence interval exceeded the established clinical margin. This conclusion is consistent with results of the superiority analyses which revealed a time effect of a greater effect size for CBT-I on that variable (pretreatment vs. posttreatment time effect; d = −0.78 for CBT-I vs. d = −0.67 for EX). However, results of the non-inferiority analysis at follow-up revealed that EX was not significantly inferior to CBT-I in reducing ISI scores. Together, these findings are contrary to our hypotheses which predicted non-inferiority of EX at posttreatment and inferiority at follow-up. They are however consistent with those obtained in a previous non-inferiority trial in cancer in which a mindfulness-based stress reduction (MBSR) intervention was found to be statistically inferior to CBT-I at posttreatment but was non-inferior at a 5-month follow-up [66] . On the other hand, in another non-inferiority trial conducted in cancer patients, a 12-week Tai Chi intervention was found to be non-inferior to CBT-I in leading to an insomnia treatment response at posttreatment (defined by a decrease ≥ 5 points on the PSQI) and this non-inferiority was sustained at 6-and 15-month follow-ups [67] .
Results of superiority analyses comparing the two groups on subjective and objective measures of sleep were partly inconsistent with results of the non-inferiority analyses. First, the lack of significant effects on actigraphic data suggested that both interventions had a modest impact on participants' objective sleep. Second, no significant between-group differences on the improvement of subjective sleep variables were observed either at posttreatment or at follow-up, as reflected by a lack of significant group-by-time interaction on all variables (except for PSQI but no significant simple effects were detected). However, the significant main time effect found on all subjective variables, as well as the similar medium to large effect sizes obtained on many variables in both groups (ds > 0.50 for ISI, PSQI, SOL, WASO, TWT, and SE) suggest that both interventions significantly improved subjective sleep.
Nevertheless, scores obtained on self-reported questionnaires (ISI and PSQI) indicated a general persistence of clinically significant sleep difficulties in both groups at posttreatment and at follow-up. In fact, remission rates of insomnia at posttreatment, defined by an ISI score < 8, were only 30.7% in the CBT-I group and 35.2% in the EX group, a difference that was not significant. Rates were even weaker when using the PSQI (score ≤ 5), attaining only 9.9% for CBT-I and 11.3% for EX group.
A first possible explanation for these mitigated results is the fact that self-administered (i.e. home-based) forms of both CBT-I and EX were used. For EX, the home-based format is the one that has been used the most frequently in previous studies assessing its effect on sleep of cancer patients [41] , but patients' adherence may not be optimal when supervision from a health professional is minimal. Hence, it is difficult to know whether effects would have been greater if a supervised program had been used. Research comparing delivery modes of EX is greatly needed [68] . Nonetheless, these results are consistent with the modest effects observed in our prior meta-analysis [41] . It is also possible that an EX intervention requires more time in order to produce a positive effect on insomnia symptoms given the previous literature showing that regular EX is associated with greater sleep improvements [69] . For CBT-I, remission rates found in the current study are weaker than what has previously been reported. Indeed, although the remission rate of insomnia obtained in our previous RCT in patients who received the same self-administered (video) CBT-I intervention (ISI score < 8; 44.3%) was lower than that found in the professionally-administered CBT-I (71.3%), it was higher than the rate obtained in this study (30.7%) [70] . In the same study, an average decrease of 6.2 points on the ISI with an effect size of d = −1.40 was observed (pretreatment vs. posttreatment), as compared to an average decrease of 4.5 points with an effect size of d = −0.78 in the current study.
Findings of our preference and integrity analyses provided some possible answers as to why CBT-I underperformed in the current study. Participants expressed a greater interest for the EX intervention when entering the study than for CBT-I. This may reflect the fact that the general benefits of EX on health are largely known. In addition, healthcare providers and society in general also greatly stress the importance to adopt a healthy lifestyle, especially after a cancer diagnosis, thus possibly increasing patients' interest in receiving some support in achieving that goal. Our findings indicating no significant between-group difference on adherence to some CBT-I strategies (regularity of sleep/wake schedule and reduce napping) suggest that, because the motivation to participate in CBT-I was lower, patients did not adhere as well to CBT-I strategies as they usually do in CBT-I trials with no EX condition. This lower adherence may have translated into more limited treatment effects.
The lack of significant between-group differences on studied outcomes could also be explained by a contamination effect of the EX condition. Indeed, 42.9% of CBT-I participants met at least one of the two EX recommendations of our EX intervention, as assessed using data from the EX diary completed during the intervention, as compared to 65.0% in the EX group, a difference that was not significant. In fact, both groups maintained a relatively similar practice of EX at each time assessment (absence of interaction and group effects) based on GLTEQ scores and actigraphy-based EX data. This high contamination effect may be due, again, to the fact that most participants (60%) had a favorable bias towards EX at baseline. With regard to the lack of a time effect, this can be explained by the fact that participants were already engaged in some levels of EX at baseline and, consequently, they did not have the capacity/possibility to increase their practice even more in only 6 weeks. Future studies should probably recruit more sedentary/less active patients to ensure a more important contrast between baseline and EX intervention levels.
Concerning the possible influence of treatment preferences, it was surprising to find that the mismatched subgroup of CBT-I participants showed the most consistent improvement across the main sleep outcomes (ISI, PSQI, and SE), while EX participants showed more consistent improvements when they were matched. This suggests that CBT-I is beneficial even when it is not the preferred option initially. This is consistent with the finding indicating that CBT-I participants reported significantly increased scores of treatment credibility and expectancies for improvement during the course of the intervention (from baseline to the 5th week) as compared to EX participants who reported decreased treatment expectancies during the same period.
Contrary to what was initially expected, CBT-I participants did not show a better sustainment of treatment gains over time than EX participants. It was initially hypothesized that EX participants would reduce their EX practice after the intervention phase (given that EX maintenance is often a challenge, especially in the absence of professional guidance), thus leading to an upsurge in their symptoms. Rather, EX participants reported a nonsignificant change (no significant time effect) in their EX practice during the entire study, including followup assessments, as assessed with the GLTEQ, as well as with actigraphy. This hypothesis was also based on the assumption that CBT-I participants would integrate in their lifestyle the main sleep recommendations proposed during this intervention, thus ensuring a long-term sustainment of treatment gains. However, this hypothesis was not confirmed by the integrity analysis, which showed that CBT-I participants did not adopt a more regular sleep/wake schedule between pretreatment and posttreatment and that both interventions led to a decrease in napping.
It is important to note that more EX participants dropped out of the study (6 vs. 2), four of whom (67%) did so during the follow-up periods. Given that patients were not asked to continue to be physically active during the follow-up period, the differential dropout rate across groups is difficult to explain. It is possible that EX patients were more likely to drop out of the study because they got less benefit from the intervention than they desired, which may have biased the follow-up results in favor of EX. Interestingly, results of a meta-analysis including 17 trials (mainly musculoskeletal trials) investigating the impact of preferences on attrition rates and outcomes reported that participants allocated to the less preferred treatment were more likely to complete follow-up assignments relative to indifferent participants [71] , which is what we found in CBT-I patients.
To our knowledge, this is the first RCT comparing an EX intervention to CBT-I for improving clinical levels of insomnia symptoms in cancer patients. Strengths of this study include methodological aspects such as the randomization, the use of a clinical threshold of insomnia at baseline as an inclusion criterion, the variety of subjective and objective sleep measures administered, and the follow-up assessments to assess the sustainment of treatment gains over time. In addition, as recommended by the ACMS, all participants underwent a personalized assessment of their physical condition before the intervention. On the other hand, the sample was small and comprised a large proportion of women (78%) with a breast cancer diagnosis (54%), thus reducing the statistical power to detect significant differences, a problem in part circumvented by the calculation of effect sizes, and limiting the generalization of the findings. The absence of statistical correction for multiple tests is another limitation. However, as mentioned previously, the non-inferiority hypothesis, based on the ISI, was the main one of this clinical trial; all other superiority analyses were exploratory in nature. The lack of a no-treatment control group is another important limitation that would have made it possible to delineate the effects due to nonspecific ingredients such as the simple passage of time and regression to the mean.
Finally, the addition of extra documentation in the EX group could have been useful to make conditions equivalent in this respect and to increase patients' adherence.
Conclusion
In conclusion, insomnia is a common problem associated with cancer and its treatment. CBT-I is now considered the gold standard for treating this condition. However, accessibility to this treatment is limited. Results of this pilot RCT suggest that a self-administered CBT-I and a home-based EX program are both efficacious in reducing insomnia symptoms with a slight advantage for CBT-I immediately after the intervention. However, these findings need to be interpreted cautiously given the high risk of contamination between the two groups and the general patients' positive bias towards EX at baseline. In the future, it would be relevant to conduct a larger scale RCT that would not specify the interventions studied when recruiting patients. An alternative would be to use a preference trial to better distinguish the treatment effects from the preference effects. Overall, this study suggests that CBT-I is still the treatment of choice for insomnia comorbid with cancer, but that an EX program could constitute an acceptable alternative.
